By The Petrie-Flom Center Open Access Week 2013: Promoting Access to Federally Funded Research Monday, October 21st, 12pm-1pm. Wasserstein Hall 4063. Lunch will be served. 2013 has seen many milestones towards improving access to biomedical research. In February, President Obama issued an Executive Order requiring most federal research agencies to implement public access policies; official guidance…
Bill of Health blogger Dov Fox was quoted in the recent article “Genetic-testing patent raises concerns about ‘designer babies’.” “‘Some people might say this is in some respects similar to dating websites to the extent you look for traits in somebody you want to have children with,’ said Dov Fox, a law professor at the…
By The Petrie-Flom Center In the first installment of our new collaboration with Genetics in Medicine, we are highlighting an article released yesterday discussing 23andMe’s controversial “designer baby” patent, which has already gotten quite a bit of attention. Here’s the press release, and an exclusive commentary from Sigrid Sterckx, one of the article’s authors, can…
By Sigrid Sterckx, as part of our collaboration with Genetics in Medicine Yesterday, 3 October, an article I wrote with three co-authors about a controversial US patent was published by the (Nature) journal Genetics in Medicine. The patent, granted last week to the Californian Direct-To-Consumer genetic testing company 23andMe, is entitled ‘Gamete donor selection based on…
Check out blogger Dov Fox‘s new op-ed over at HuffPo discussing 23andMe’s Designer Baby Patent. Here’s a quick taste: Even if 23andMe doesn’t bring its donor selection technique to market, there’s still reason to resist granting such patents in the first place. Patents do more, after all, than incentive innovators to disclose their inventions to the…
By The Petrie-Flom Center Healthcare Compliance Certification Program 2014 Health Law Student Scholarships Seton Hall University School of Law Center for Health & Pharmaceutical Law & Policy The Healthcare Compliance Certification Program is a multi-day educational program that addresses the myriad of legal and compliance issues faced by the pharmaceutical and medical device industries. Purpose: This award recognizes…
Check out this nice write up of PFC Academic Fellow Nicholson Price‘s paper, Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing, over at the Written Description IP blog. Says blogger Camilla Alexandra Hrdy, “Price’s paper leads to a host of new and interesting questions, and his thorough research revealing potential shortcomings of the FDA approval…
In case you missed it live on Monday evening, video from the Petrie-Flom Center’s event “Gene Patenting, the Supreme Court’s Myriad Decision, and the Future of Biotechnology” (co-sponsored by the Broad Institute) is now available here. 09/27/13 UPDATE: Our intern Fatima Mirza also wrote up this summary: At this event, a distinguished panel of law and…
By Marcia Boumil and Gregory Curfman In 2013 the U.S. Supreme Court issued two important rulings in cases involving the marketing of generic drugs. In Federal Trade Commission v. Actavis, the Court addressed the law governing a controversial pharmaceutical marketing practice known as reverse payment agreements, or pay for delay – a byproduct of the Hatch-Waxman…
By Nicholson Price There’s a lot of talk and research about the drug industry, including its levels of innovation, its pricing patterns, transparency of clinical trials, industry changes over time, and how the industry is and should be regulated. But one thing that usually flies way under the radar is the question of actually making…
